

In the Claims

1-42 (canceled).

43 (new). A co-crystal comprising an API and a co-crystal former selected from:

- (a) carbamazepine and saccharin;
- (b) carbamazepine and nicotinamide;
- (c) carbamazepine and trimesic acid;
- (d) celecoxib and nicotinamide;
- (e) celecoxib and 18-crown-6;
- (f) 5-fluorouracil and urea;
- (g) acetaminophen and 4,4'-bipyridine;
- (h) phenytoin and pyridone;
- (i) aspirin and 4,4'-bipyridine;
- (j) ibuprofen and 4,4'-bipyridine;
- (k) flurbiprofen and 4,4'-bipyridine;
- (l) flurbiprofen and trans-1,2-bis(4-pyridyl) ethylene;
- (m) carbamazepine and p-phthalaldehyde;
- (n) carbamazepine and 2,6-pyridinedicarboxylic acid;
- (o) carbamazepine and 5-nitroisophthalic acid;
- (p) carbamazepine and 1,3,5,7-adamantane tetracarboxylic acid; or
- (q) carbamazepine and benzoquinone.

44 (new). The co-crystal according to claim 43, wherein said co-crystal comprises carbamazepine and saccharin.

45 (new). The co-crystal according to claim 43, wherein said co-crystal comprises carbamazepine and nicotinamide.

46 (new). The co-crystal according to claim 43, wherein said co-crystal comprises carbamazepine and trimesic acid.

47 (new). The co-crystal according to claim 43, wherein said co-crystal comprises celecoxib and nicotinamide.

48 (new). The co-crystal according to claim 43, wherein said co-crystal comprises celecoxib and 18-crown-6.

49 (new). The co-crystal according to claim 43, wherein said co-crystal comprises 5-fluorouracil and urea.

50 (new). The co-crystal according to claim 43, wherein said co-crystal comprises acetaminophen and 4,4'-bipyridine.

51 (new). The co-crystal according to claim 43, wherein said co-crystal comprises phenytoin and pyridine.

52 (new). The co-crystal according to claim 43, wherein said co-crystal comprises aspirin and 4,4'-bipyridine.

53 (new). The co-crystal according to claim 43, wherein said co-crystal comprises ibuprofen and 4,4'-bipyridine.

54 (new). The co-crystal according to claim 43, wherein said co-crystal comprises flurbiprofen and 4,4'-bipyridine.

55 (new). The co-crystal according to claim 43, wherein said co-crystal comprises flurbiprofen and trans-1,2-bis(4-pyridyl) ethylene.

56 (new). The co-crystal according to claim 43, wherein said co-crystal comprises carbamazepine and p-phthalaldehyde.

57 (new). The co-crystal according to claim 43, wherein said co-crystal comprises carbamazepine and 2,6-pyridinecarboxylic acid.

58 (new). The co-crystal according to claim 43, wherein said co-crystal comprises carbamazepine and 5-nitroisophthalic acid.

59 (new). The co-crystal according to claim 43, wherein said co-crystal comprises carbamazepine and 1,3,5,7-adamantane tetracarboxylic acid.

60 (new). The co-crystal according to claim 43, wherein said co-crystal comprises carbamazepine and benzoquinone.

61 (new). A pharmaceutical composition comprising a pharmaceutically acceptable diluent, excipient, or carrier and a co-crystal comprising an API and a co-crystal former selected from:

- (a) carbamazepine and saccharin;
- (b) carbamazepine and nicotinamide;
- (c) carbamazepine and trimesic acid;
- (d) celecoxib and nicotinamide;
- (e) celecoxib and 18-crown-6;
- (f) 5-fluorouracil and urea;
- (g) acetaminophen and 4,4'-bipyridine;
- (h) phenytoin and pyridone;
- (i) aspirin and 4,4'-bipyridine;
- (j) ibuprofen and 4,4'-bipyridine;
- (k) flurbiprofen and 4,4'-bipyridine;

- (l) flurbiprofen and trans-1,2-bis(4-pyridyl) ethylene;
- (m) carbamazepine and p-phthalaldehyde;
- (n) carbamazepine and 2,6-pyridinecarboxylic acid;
- (o) carbamazepine and 5-nitroisophthalic acid;
- (p) carbamazepine and 1,3,5,7-adamantane tetracarboxylic acid; or
- (q) carbamazepine and benzoquinone.

62 (new). The pharmaceutical composition according to claim 61, wherein said co-crystal comprises carbamazepine and saccharin;

63 (new). The pharmaceutical composition according to claim 61, wherein said co-crystal comprises carbamazepine and nicotinamide.

64 (new). The pharmaceutical composition according to claim 61, wherein said co-crystal comprises carbamazepine and trimesic acid.

65 (new). The pharmaceutical composition according to claim 61, wherein said co-crystal comprises celecoxib and nicotinamide.

66 (new). The pharmaceutical composition according to claim 61, wherein said co-crystal comprises celecoxib and 18-crown-6.

67 (new). The pharmaceutical composition according to claim 61, wherein said co-crystal comprises 5-fluorouracil and urea.

68 (new). The pharmaceutical composition according to claim 61, wherein said co-crystal comprises acetaminophen and 4,4'-bipyridine.

69 (new). The pharmaceutical composition according to claim 61, wherein said co-crystal comprises phenytoin and pyridine.

70 (new). The pharmaceutical composition according to claim 61, wherein said co-crystal comprises aspirin and 4,4'-bipyridine.

71 (new). The pharmaceutical composition according to claim 61, wherein said co-crystal comprises ibuprofen and 4,4'-bipyridine.

72 (new). The pharmaceutical composition according to claim 61, wherein said co-crystal comprises flurbiprofen and 4,4'-bipyridine.

73 (new). The pharmaceutical composition according to claim 61, wherein said co-crystal comprises flurbiprofen and trans-1,2-bis(4-pyridyl) ethylene.

74 (new). The pharmaceutical composition according to claim 61, wherein said co-crystal comprises carbamazepine and p-phthalaldehyde.

75 (new). The pharmaceutical composition according to claim 61, wherein said co-crystal comprises carbamazepine and 2,6-pyridinedicarboxylic acid.

76 (new). The pharmaceutical composition according to claim 61, wherein said co-crystal comprises carbamazepine and 5-nitroisophthalic acid.

77 (new). The pharmaceutical composition according to claim 61, wherein said co-crystal comprises carbamazepine and 1,3,5,7-adamantane tetracarboxylic acid.

78 (new). The pharmaceutical composition according to claim 61, wherein said co-crystal comprises carbamazepine and benzoquinone.